Skip to main content
Premium Trial:

Request an Annual Quote

Harvard, Dana-Farber License Screening Platform to Acetylon

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.

The partners did not provide details on the screening and optimization platform.

Harvard and Dana-Farber received equity from Acetylon and also will receive downstream royalty and milestone payments, under terms of the licensing agreement.

Boston-based Acetylon was founded on core technology developed at Harvard and Dana-Farber. The firm is developing drug candidates based on next-generation Class II-selective HDAC inhibitors.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.